The Asociación Española Contra el Cáncer (AECC) presents a prize for a study that reveals the capacity of the CPEB4 protein to prevent fatty liver disease.
The research was led by Raúl Méndez from IRB Barcelona and Mercedes Fernández from IDIBAPS.
The Asociación Española Contra el Cáncer (AECC) has given a prize to a study called Circadian- and UPR-dependent control of CPEB4 mediates a translational response to counteract hepatic steatosis under ER stress, led by Raúl Méndez, head of the Translational Control of Cell Cycle and Differentiation Lab at IRB Barcelona, and Mercedes Fernández, from IDIBAPS.
The article has been awarded as the "Best Publication" of the II Contest of disclosure and involvement in cancer research of the AECC. The AECC contest aims to recognize the actions that have managed to encourage the dissemination of science among the scientific community and society.
The research, published in the journal Nature Cell Biology, reveals the capacity of the CPEB4 protein to prevent fatty liver, the most prevalent chronic of this organ that is caused by the excessive fat deposits in liver cells. IRB Barcelona prepared the press release and led the dissemination of the research through different channels, in coordination with IDIBAPS.
Link to the press release.